Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of MXN 2.74 trillion. The enterprise value is 3.00 trillion.

Market Cap	2.74T
Enterprise Value	3.00T

Important Dates

The next estimated earnings date is Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Sep 15, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	+1.02%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.09%
Owned by Institutions (%)	88.30%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 18.39 and the forward PE ratio is 14.55.

PE Ratio	18.39
Forward PE	14.55
PS Ratio	5.13
PB Ratio	6.95
P/TBV Ratio	n/a
P/FCF Ratio	16.28
P/OCF Ratio	15.43
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.52, with an EV/FCF ratio of 17.84.

EV / Earnings	20.15
EV / Sales	5.66
EV / EBITDA	11.52
EV / EBIT	14.49
EV / FCF	17.84

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.16.

Current Ratio	1.45
Quick Ratio	1.10
Debt / Equity	1.16
Debt / EBITDA	1.74
Debt / FCF	2.72
Interest Coverage	11.17

Financial Efficiency

Return on equity (ROE) is 40.71% and return on invested capital (ROIC) is 16.14%.

Return on Equity (ROE)	40.71%
Return on Assets (ROA)	12.57%
Return on Invested Capital (ROIC)	16.14%
Return on Capital Employed (ROCE)	24.59%
Revenue Per Employee	30.31M
Profits Per Employee	8.45M
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.39

Taxes

In the past 12 months, Gilead Sciences has paid 32.58 billion in taxes.

Income Tax	32.58B
Effective Tax Rate	17.96%

Stock Price Statistics

The stock price has increased by +19.18% in the last 52 weeks. The beta is 0.33, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.33
52-Week Price Change	+19.18%
50-Day Moving Average	2,167.24
200-Day Moving Average	1,697.86
Relative Strength Index (RSI)	48.67
Average Volume (20 Days)	1,127

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.29

Income Statement

In the last 12 months, Gilead Sciences had revenue of MXN 533.52 billion and earned 148.76 billion in profits. Earnings per share was 117.81.

Revenue	533.52B
Gross Profit	419.96B
Operating Income	208.55B
Pretax Income	181.33B
Net Income	148.76B
EBITDA	259.29B
EBIT	208.55B
Earnings Per Share (EPS)	117.81

Full Income Statement

Balance Sheet

The company has 155.73 billion in cash and 457.47 billion in debt, giving a net cash position of -264.97 billion.

Cash & Cash Equivalents	155.73B
Total Debt	457.47B
Net Cash	-264.97B
Net Cash Per Share	n/a
Equity (Book Value)	393.55B
Book Value Per Share	318.11
Working Capital	102.28B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 177.31 billion and capital expenditures -9.26 billion, giving a free cash flow of 168.05 billion.

Operating Cash Flow	177.31B
Capital Expenditures	-9.26B
Free Cash Flow	168.05B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.72%, with operating and profit margins of 39.09% and 27.88%.

Gross Margin	78.72%
Operating Margin	39.09%
Pretax Margin	33.99%
Profit Margin	27.88%
EBITDA Margin	48.60%
EBIT Margin	39.09%
FCF Margin	31.50%

Dividends & Yields

This stock pays an annual dividend of 60.96, which amounts to a dividend yield of 2.68%.

Dividend Per Share	60.96
Dividend Yield	2.68%
Dividend Growth (YoY)	10.12%
Years of Dividend Growth	1
Payout Ratio	49.10%
Buyback Yield	-1.02%
Shareholder Yield	1.66%
Earnings Yield	5.44%
FCF Yield	6.14%

Dividend Details

Stock Splits

The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.

Last Split Date	Jan 28, 2013
Split Type	Forward
Split Ratio	2

Scores

Gilead Sciences has an Altman Z-Score of 3.64 and a Piotroski F-Score of 7.

Altman Z-Score	3.64
Piotroski F-Score	7